Pharmacokinetics of nilvadipine after single oral doses in healthy volunteers.
Forty healthy male Caucasian volunteers were randomly assigned to five treatment groups to receive a placebo or a 4, 8, 12, 16 or 20 mg dose of nilvadipine. The drug was well tolerated by the subjects at all dose levels. Pharmacokinetic parameters for nilvadipine were determined using model-independent methods. There were no significant differences (p greater than 0.05) in the time to the maximum plasma concentration (Cmax) (tmax), the elimination half-life or the mean residence time among the five treatment groups. Up to doses of about 12 mg, there was a linear relationship between dose and Cmax or area under the plasma concentration-time curve (AUCO----infinity). At doses of 16 and 20 mg, the relationship between dose and Cmax or AUCO----infinity was no longer linear, suggesting that the pharmacokinetics of the drug after single oral doses greater than about 12 mg may be dose-dependent, probably due to concentration-dependent first-pass hepatic elimination of the drug.
Cheung
W K
WK
Medical Research Division, American Cyanamid Company, Pearl River, New York 10965.
Woodward
D L
DL
Shin
K
K
Hibberd
M
M
Pearse
S
S
Desjardins
R E
RE
Yacobi
A
A
Silber
B M
BM
D000284:Administration, Oral; D000328:Adult; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D006801:Humans; D008297:Male; D009543:Nifedipine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D011897:Random Allocation
C035100:nilvadipine; D009543:Nifedipine